The New Standard in Anticoagulation: Analyzing the Global Apixaban Market
For over half a century, warfarin was the only oral option for patients needing long-term anticoagulation to prevent strokes and blood clots. However, warfarin's unpredictable dosing and frequent need for blood monitoring made it a difficult drug for both patients and doctors to manage. The arrival of Direct Oral Anticoagulants (DOACs), with Apixaban at the forefront, has completely transformed...
0 Комментарии 0 Поделились 50 Просмотры 0 предпросмотр